Breaking News, Promotions & Moves

Hansa Biopharma Welcomes Evan Ballantyne as Chief Financial Officer

Ballantyne brings more than 30 years’ experience as a senior financial executive in both public and private life science companies.

Author Image

By: Charlie Sternberg

Associate Editor

Hansa Biopharma, which recently announced plans to restructure, has appointed Evan Ballantyne as Chief Financial Officer (CFO), effective March 1, 2024. He succeeds Donato Spota, who will leave the company on February 28.   As CFO, Ballantyne will be responsible for developing and implementing the company’s corporate financial strategy and activities including financial reporting and investor relations (IR). He will report to President & Chief Executive Officer Søren Tulstrup and ser...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters